

APPLICANTS: **Kurtis et al.**
U.S.S.N.: **10/008,340**

In the claims:

Claim 1 (previously cancelled)

Claim 2 (previously amended): The sustained drug delivery device of claim 10, wherein the helminth is a hookworm, roundworm, pinworm or tapeworm.

Claim 3 (previously cancelled)

Claim 4 (previously amended): The sustained drug delivery device of claim 11, wherein the Schistosome species is *Schistosoma mansoni*, *Schistosoma japonicum*, or *Schistosoma hematobium*.

Claim 5 (previously amended): The sustained drug delivery device of claim 10, wherein the bioactive agent is a polypeptide.

Claim 6 (previously amended): The sustained drug delivery device of claim 5, wherein the polypeptide is a secreted polypeptide.

Claim 7 (previously amended): The sustained drug delivery device of claim 6, wherein the polypeptide is a post-translationally modified polypeptide.

Claim 8 (previously amended): The sustained drug delivery device of claim 7, wherein the post-translational modification is glycosylation.

Claim 9 (previously amended): The sustained drug delivery device of claim 5, wherein the polypeptide is a cytokine, enzyme, hormone, or neurotransmitter.

Claim 10 (currently amended) A sustained drug delivery device comprising a stably transformed helminth male prepared according to a method comprising

introducing a nucleic acid encoding a bioactive agent into an ovary of a female helminth, wherein said nucleic acid is provided as part of an adeno-associated virus vector;

selecting a female helminth stably transformed with said bioactive agent-encoding nucleic acid and adeno-associated virus vector;

crossing said stably transformed female helminth to a non-transformed male helminth; and

isolating a progeny male containing said stably transformed nucleic acid bioactive agent-encoding nucleic acid and adeno-associated virus vector;

thereby making a sustained drug delivery device.

Claim 11 (previously amended): The sustained delivery device of claim 10, wherein the helminth is a Schistosome species.

Claim 12 (original claim): A miracidia containing the sustained drug delivery device of claim 11.

Claim 13 (original claim): A snail containing the miracidia of claim 12.

Claim 14 (original claim): A cercaria comprising the sustained drug delivery device of claim 11.

APPLICANTS: **Kurtis et al.**
U.S.S.N.: **10/008,340**

Claim 15. (original claim): A pharmaceutical composition comprising the sustained delivery device of claim 11 and a pharmaceutically acceptable carrier.

Claims 16-20 (previously cancelled)